Eli Lilly and (LLY) Revenue — Quarter Ended Dec 31, 2023
Revenue for the reported period decreased slightly from the prior period, while increasing significantly compared with the same period a year ago. This mixed movement comes after several periods of consecutive growth.
Key takeaway
Quarter ended Dec 31, 2023 · FY2023 Q4
Revenue for the reported period decreased slightly from the prior period, while increasing significantly compared with the same period a year ago. This mixed movement comes after several periods of consecutive growth.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$9.4B
Revenue reported for this quarter.
Quarter-over-quarter
-1.5%
Change from the immediately preceding quarter.
Year-over-year
+28.1%
Change from the comparable year-ago quarter.
Trailing four quarters
$34.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2023 | $7B | -10.9% |
| Jun 30, 2023 | $8.3B | +28.1% |
| Sep 30, 2023 | $9.5B | +36.8% |
| Dec 31, 2023 | $9.4B | +28.1% |
Revenue performance
The revenue figure reflects a small contraction from the immediately preceding period, but a strong year-over-year advance. The company has maintained elevated revenue levels despite the quarterly dip.
Quarterly comparison
Versus the prior period, revenue edged lower, breaking a series of sequential increases. In contrast, revenue showed a marked rise compared with the same period one year earlier, consistent with the robust growth trajectory.
What to watch
Monitor whether the company can reverse this sequential decline and resume growth in the coming period, given the backdrop of significant capacity investments.